This site is intended for Healthcare professionals only.

Suven Life Sciences begins clinical trial of anti-depressant


Suven Life Sciences begins clinical trial of anti-depressant

New Delhi: Drug firm Suven Life Sciences announced initiation of phase 1 clinical trial and first dosing of a chemical entity intended for the treatment of a major depressive disorder.

In a BSE filing, Suven Life Sciences said its NCESUVN- 911, a “novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing… and the topline results from the study is expected during the quarter January-March 2018″.

Suven Life CEO Venkat Jasti said: “Progression of SUVN-911 into phase 1 clinical development is a significant achievement in enhancing our clinical pipeline beyond Dementia into mental illness arena, Major Depressive Disorder (MDD).”

Suven Life said the global antidepressant market is valued over $20 billion.

Suven Life Sciences shares were trading 1.01 per cent up at Rs. 75.80 on BSE in morning trade.



Source: PTI
0 comment(s) on Suven Life Sciences begins clinical trial of anti-depressant

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted